NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:**  Wednesday 13 September 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair, Topics 2 and 3) Present for all items
2. Dr Stephen Smith (Chair, Topic 1) Present for all items
3. Dr Matthew Bradley Items 1.1 to 5.1.3,

Items 6.1.1 to 6.2.2

1. Professor Sofia Dias Present for all items
2. Christopher Herring Present for all items
3. Dr Andrew Hitchings Present for all items
4. Dr Robert Hodgson Present for all items
5. Dr Guy Makin Present for all items
6. Dr Philip Mallender Present for all items
7. Professor David Meads Present for all items
8. Giles Monnickendam Items 1.1 to 4.2.2,

Items 6.1.1 to 6.2.2

1. Dr Malcolm Oswald Present for all items
2. Dr Alistair Patton Items 6.1.1 to 6.2.2
3. Dr Rebecca Payne Present for all items
4. Carole Pitkeathley Present for all items
5. Dr Raju Reddy Present for all items
6. Dr Ben Searle Present for all items
7. Professor John Watkins Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Items 1.1 to 4.2.2,

Items 6.1.1 to 6.2.2

Kate Moore, Project Manager Items 1.1 to 4.2.2,

Items 6.1.1 to 6.2.2

Christian Griffiths, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Janet Boadu, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Ross Dent, Associate Director Items 5.1.1 to 5.2.2

Louise Jafferally, Project Manager Items 5.1.1 to 5.2.2

Caron Jones, Heath Technology Assessment Adviser Items 5.1.1 to 5.2.2

Dilan Savani, Heath Technology Assessment Analyst Items 5.1.1 to 5.2.2

Victoria Kelly, Heath Technology Assessment Adviser Items 6.1.1 to 6.2.2

Victoria Gillis-Elliott, Heath Technology Assessment Analyst Items 6.1.1 to 6.2.2

Jacoline Bouvy, Programme Director Present for all items

External assessment group representatives present

Tracey Jhita, BMJ Items 1.1 to 4.1.3

Ben Farrar, BMJ Items 1.1 to 4.1.3

Steve Edwards, BMJ Items 1.1 to 4.1.3

Dr Geoff Frampton, University of Southampton Items 5.1.1 to 5.1.3

Joanne Lord, University of Southampton Items 5.1.1 to 5.1.3

Caroline Farmer, PenTAG Items 6.1.1 to 6.1.4

Ed Wilson, PenTAG Items 6.1.1 to 6.1.4

Clinical, Patient & NHS England experts present

Professor Adrian Bloor, Consultant Haematologist, clinical expert nominated by NHS England Items 1.1 to 4.1.3

Dr Jose Ros-Soto, Consultant Haematologist, clinical expert nominated by Anthony Nolan Items 1.1 to 4.1.3

Daniel Yeates, Patient expert, nominated by Anthony Nolan Items 1.1 to 4.1.3

Anna Kafkalias, National Programme of Care Manager, Blood and Infection, NHS commissioning expert nominated by NHS England Specialised Commissioning

Items 1.1 to 4.1.3

Dr Sanjeev Patel, Clinical Lead, IMF, NHSE Items 5.1.1 to 6.2.2

Dr Jennifer Spillane, Neurology Consultant – clinical expert, nominated by Alexion Items 5.1.1 to 5.1.3

Dr Maria Isabel Leite, Consultant Neurologist and Associate Professor – clinical expert, nominated by Myaware Items 5.1.1 to 5.1.3

Amanda Hayes, Patient expert, nominated by Muscular Dystrophy UK

Items 5.1.1 to 5.1.3

Tracey Maitland, National Support Co-Ordinator, Myaware – Patient expert, nominated by Myaware Items 5.1.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Dr Stephen Smith, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Martin Bradley, Elliot Dash, Andrew Fox, Dr Bernard Khoo, Dr Ivan Koychev, Dr Nathan Moore and Chris Parker.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 12 July 2023 and Thursday 10 August 2023

### Appraisal of belumosudil for treating chronic graft versus host disease after 2 or more lines of systemic therapy [ID4021]

* 1. Part 1 – Open session
     1. The Chair, Dr Stephen Smith, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Sanofi.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11136).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carole Pitkeathely, Dr Andrew Hitchings and Giles Monnickendam.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11136>

### Appraisal of Ravulizumab for treating generalised myasthenia gravis [ID4019]

* 1. Part 1 – Open session
     1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Alexion.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10987).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carole Pitkeathley, Dr Raju Reddy and Dr Robert Hodgson.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10987>

### Appraisal of Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]

* 1. Part 1 – Open session
     1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from CSL Behring.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10699).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by The Chair.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10699>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 12 October 2023 and will start promptly at 09:15am.